Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.

OBJECTIVE Since excessive fibrinolysis during cardiac surgery is frequently associated with abnormal perioperative bleeding, many authors have advocated prophylactic use of antifibrinolytic drugs to prevent hemorrhagic disorders. We compared the effects of tranexamic acid (a synthetic antifibrinolytic drug) with aprotinin (a natural derivative product with antifibrinolytic properties) on perioperative bleeding and the need for allogeneic transfusions. METHODS In a single-center prospective randomized unblinded trial, 1040 consecutive patients undergoing primary, elective cardiac operations with cardiopulmonary bypass received either high-dose aprotinin or tranexamic acid. The aprotinin group (518 patients) received 280 mg in 20 minutes before the skin incision, 280 mg in the priming solution of the extracorporeal circuit, and a continuous infusion of 70 mg/h throughout the operation. The tranexamic acid group (522 patients) received 1 g in 20 minutes before the skin incision, 500 mg in the priming solution of the extracorporeal circuit, and a continuous infusion of 400 mg/h during the operation. Postoperative bleeding, perioperative transfusions, and hematologic variables were evaluated at fixed times. Postoperative thrombotic complications, intubation time, intensive care unit stay, and hospital stay were recorded. RESULTS Postoperative bleeding was similar in the 2 groups: aprotinin 250 mL (150-400 mL) versus tranexamic acid 300 mL (200-450 mL) (median and 25th-75th quartiles), median difference of 50 mL (95% confidence intervals, 0-50 mL). The number of transfusions and the outcome did not differ. CONCLUSIONS Tranexamic acid and aprotinin show similar clinical effects on bleeding and allogeneic transfusion in patients undergoing primary elective heart operations. Since tranexamic acid is about 100 times cheaper than aprotinin, its use is preferable in this type of patient.

[1]  O. Alfieri,et al.  Hemostatic effects of aprotinin, tranexamic acid and ϵ-aminocaproic acid in primary cardiac surgery , 1999 .

[2]  J. Norberto,et al.  Severe anaphylactic reaction after primary exposure to aprotinin. , 1999, The Annals of thoracic surgery.

[3]  B. Chaitman,et al.  Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. , 1998, The Journal of thoracic and cardiovascular surgery.

[4]  S. Westaby,et al.  Aprotinin and vein graft occlusion--the controversy continues. , 1998, The Journal of thoracic and cardiovascular surgery.

[5]  P. Mongan,et al.  Tranexamic Acid and Aprotinin Reduce Postoperative Bleeding and Transfusions During Primary Coronary Revascularization , 1998, Anesthesia and analgesia.

[6]  J. Copeland,et al.  Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. , 1996, The Annals of thoracic surgery.

[7]  L. Muhlbaier,et al.  Aprotinin: safe and effective only with the full-dose regimen. , 1996, The Annals of thoracic surgery.

[8]  G. Ruvolo,et al.  Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. , 1996, The Journal of cardiovascular surgery.

[9]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[10]  L. Goodnough,et al.  Aprotinin Prolongs Whole Blood Activated Partial Thromboplastin Time but Not Whole Blood Prothrombin Time in Patients Undergoing Cardiac Surgery , 1995, Anesthesia and analgesia.

[11]  J. Carroll,et al.  Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. , 1995, The Journal of thoracic and cardiovascular surgery.

[12]  A. Carpentier,et al.  [Fibrinolytic inhibitors and prevention of bleeding in cardiac valve surgery. Comparison of tranexamic acid and high dose aprotinin]. , 1995, Archives des maladies du coeur et des vaisseaux.

[13]  T. Treasure,et al.  Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. , 1995, The Annals of thoracic surgery.

[14]  J. E. Doran,et al.  Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. , 1994, The Journal of thoracic and cardiovascular surgery.

[15]  R. Radovancevic,et al.  The hematologic effects of cardiopulmonary bypass and the use of hemotherapy in coronary artery bypass grafting. , 1994, Archives of pathology & laboratory medicine.

[16]  G. Guiraudon,et al.  Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. , 1994, The Journal of thoracic and cardiovascular surgery.

[17]  Z. Su,et al.  Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery , 1993 .

[18]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[19]  H. Lijnen,et al.  Basic and Clinical Aspects of Fibrinolysis and Thrombolysis , 1991 .

[20]  W. Scott,et al.  Blood conservation in cardiac surgery. , 1990, The Annals of thoracic surgery.

[21]  D. Royston,et al.  The serine antiprotease aprotinin (Trasylol): a novel approach to reducing postoperative bleeding. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  D. Cosgrove,et al.  Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.

[23]  K. M. Taylor,et al.  EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.

[24]  W. Dietrich,et al.  Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. , 1997, The Journal of thoracic and cardiovascular surgery.

[25]  X. Moreau,et al.  Comparaison des effets de l’aprotinine et de l’acide tranexamique sur le saignement en chirurgie cardiaque , 1995 .

[26]  F. Tomai,et al.  Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. , 1995, Texas Heart Institute journal.

[27]  I. Goel,et al.  Prophylactic tranexamic acid decreases bleeding after cardiac operations. , 1990, The Journal of thoracic and cardiovascular surgery.